Hematology
Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.
Recent Discussions
In a patient with Waldenstrom's macroglobulinemia doing well and feeling better on ibrutinib & rituximab, but with a rising IgM, do you switch treatment or continue?
A lot depends on the pace of increase of the IgM and the line of therapy. If the pace is rapid, I would think about changing therapy. If the pace of increase is small and the patient is asymptomatic, you could continue a little longer. If planning to changing therapy, it may be reasonable to restage...
Do you routinely order double-hit assessment in cutaneous DLBCL?
There are certainly reported cases of primary cutaneous DLBCL that harbor double-hit mutations. Guidelines do not distinguish the workup of cutaneous DLBCL from other sites, and if a skin DLBCL were to be of germinal center immunophenotype with IHC expression of myc and bcl2 and/or bcl6, FISH would ...
Would detection of an adverse cytogenetic marker such as dup(1q) alone in the setting of MGUS satisfy criteria for a diagnosis of multiple myeloma?
Short answer, no.Longer answer -The important transition between MGUS/SMM to MM is CRAB criteria (hypercalcemia, renal disease, anemia, bone lesions), OR the development of a myeloma defining events -- >60% clonal plasma cells on bone marrow, multiple lesions on MRI, or FLC ratio > 100. These myelom...
What is your preferred chemotherapy regimen for a fit younger patient with mantle cell lymphoma?
For a young fit patient with mantle cell lymphoma not suitable for observation and in need of treatment, without contraindications to intensive therapy, my preferred approach is to use the MCL Younger strategy of alternating RCHOP and cytarabine-based therapy as induction. I will routinely substitut...
What recommendations do you make regarding the use of biologics for uncontrolled Crohn's disease in patient's who have a history of DLBCL that developed while on infliximab and azathioprine and whose lymphoma is essentially cured?
This is a frequent question without a clear answer. There has not been a randomized study of anti-auto-immune therapy strategies to define the risk of a relapse or secondary lymphoma in patients with a clear need for treatment. I recommend the patient work with their rheumatologist to start a low i...
How would you manage CML first-line second generation TKI with a best response of MMR 4, but now with a loss of MMR with more than one log response loss but still in complete cytogenetic remission and mutation panel negative?
The easiest would be to repeat the test in 1 month or so. If the results show persistently increased levels, then I would monitor the patient closely. I would also review any new medications for possible drug to drug interactions. I would also review the patient's adherence, does the patient still h...
Is there currently a role for adding venetoclax to a hypomethylating agent (HMA) after failure of single-agent HMA therapy in MDS?
For patients with MDS who have failed single-agent HMAs, there is an intriguing small retrospective series suggesting that adding on Venetoclax at the time of HMA failure can lead to responses (Ball et al., PMID 32589727). Because of the retrospective nature of this publication and the small numbers...
How would you manage a patient with primary CNS lymphoma who is not a candidate for high-dose methotrexate?
This is a relatively rare situation in my experience, but I think WBRT is the second most active agent for PCNSL after high-dose MTX, so if MTX is not possible, I would strongly consider WBRT. Hypothetically, if patient has good PS and you are going for "curative intent", the standard WBRT alone app...
How do you manage classical early stage Hodgkin lymphoma patients when an ESR is not checked as part of their workup?
I personally don't think ESR plays a huge factor in the management of early stage Hodgkin Lymphoma now in the era of PET-adapted treatment selection. So, if a patient has very favorable stage I-IIA HL meeting all other criteria by the GHSH study and is interested to not have combined modality treatm...
With recent measles outbreaks occurring in the US, would you consider offering multiple myeloma patients s/p ASCT on maintenance treatment vaccination, or an alternate means of immunity?
Measles is on the rise and protection is appealing. The current guidelines for adult immunizations are not clear what patients with monoclonal gammopathy (MGUS), smoldering myeloma (SMM), or multiple myeloma should do. Are they all immunocompromised? Are they all immunocompromised to the same amount...